Holen Sie sich die Stockscreener-App
20.19
2.32%
-0.42
Schlusskurs vom Vortag:
$20.61
Offen:
$20.45
24-Stunden-Volumen:
117.70K
Relative Volume:
0.15
Marktkapitalisierung:
$2.90B
Einnahmen:
$340.81M
Nettoeinkommen (Verlust:
$-419.65M
KGV:
-18.52
EPS:
-1.09
Netto-Cashflow:
$-402.10M
1W Leistung:
-3.12%
1M Leistung:
-19.47%
6M Leistung:
-13.30%
1J Leistung:
-6.19%
1-Tages-Spanne:
$19.93
$20.51
1-Wochen-Bereich:
$19.93
$21.64
52-Wochen-Spanne:
$14.56
$33.33
Denali Therapeutics Inc Stock (DNLI) Company Profile
Firmenname
Denali Therapeutics Inc
Sektor
Branche
Telefon
(650) 866-8548
Adresse
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Vergleichen Sie DNLI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
20.15 | 2.90B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
401.95 | 103.35B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
703.91 | 77.35B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.07 | 37.04B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.57 | 30.14B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.21 | 26.97B | 3.30B | -501.07M | 1.03B | -2.1146 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-16 | Hochstufung | Stifel | Hold → Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-10-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-09-06 | Eingeleitet | B. Riley Securities | Buy |
| 2023-01-30 | Eingeleitet | SVB Securities | Outperform |
| 2022-12-05 | Eingeleitet | Cowen | Outperform |
| 2022-11-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-11-02 | Eingeleitet | BofA Securities | Buy |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-09-21 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-01 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-05-18 | Eingeleitet | UBS | Buy |
| 2021-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-02-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-02-24 | Eingeleitet | Jefferies | Buy |
| 2020-02-19 | Eingeleitet | Stifel | Hold |
| 2020-01-27 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-26 | Eingeleitet | Wedbush | Neutral |
| 2019-09-13 | Eingeleitet | Nomura | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-11-12 | Eingeleitet | Janney | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-01-02 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Eingeleitet | Goldman | Neutral |
| 2018-01-02 | Eingeleitet | JP Morgan | Overweight |
| 2018-01-02 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Denali Therapeutics Inc Aktie (DNLI) Neueste Nachrichten
Principal Financial Group Inc. Acquires 149,939 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Geode Capital Management LLC Sells 27,061 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Purchased by Barclays PLC - MarketBeat
Denali Therapeutics upgraded to Buy from Hold at Stifel - Yahoo Finance
Y Intercept Hong Kong Ltd Sells 25,369 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Shares Gap UpTime to Buy? - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Upgraded to Buy at Stifel Nicolaus - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $38.90 Average PT from Brokerages - MarketBeat
Nomura Asset Management Co. Ltd. Buys Shares of 65,033 Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
State Street Corp Sells 182,779 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
When (DNLI) Moves Investors should Listen - Stock Traders Daily
We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely - Simply Wall St
Point72 Asset Management L.P. Trims Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Wellington Management Group LLP Has $312.49 Million Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Denali Starts Dosing in Phase II Parkinson's Disease Study - MSN
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report? - Yahoo Finance
Temasek Holdings Private Ltd Lowers Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Holocene Advisors LP Has $2.84 Million Stake in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
The Manufacturers Life Insurance Company Has $6.03 Million Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Charles Schwab Investment Management Inc. Trims Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics Announces First Participant Dosed in - GlobeNewswire
Denali Therapeutics Launches Key Phase 2a Trial for Breakthrough Parkinson's Treatment - StockTitan
26,900 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Purchased by Erste Asset Management GmbH - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Position Boosted by Cinctive Capital Management LP - MarketBeat
Fmr LLC Purchases 7,596,508 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Wasatch Advisors LP Reduces Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Bought by Fred Alger Management LLC - MarketBeat
Denali Therapeutics Getting Closer To Key Technical Measure - MSN
Algert Global LLC Has $1.42 Million Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
29,543 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Purchased by Intech Investment Management LLC - MarketBeat
Fisher Asset Management LLC Buys 69,223 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
PTC halts development of ALS drug after trial miss - The Pharma Letter
Victory Capital Management Inc. Has $1.16 Million Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Objective long/short (DNLI) Report - Stock Traders Daily
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $38.90 Consensus PT from Analysts - MarketBeat
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging - MSN
Denali Therapeutics updates bylaws, aligns with SEC rules - Investing.com India
Denali Therapeutics updates bylaws, aligns with SEC rules By Investing.com - Investing.com UK
Denali Therapeutics (NASDAQ:DNLI) Trading Down 8.3%Here's What Happened - MarketBeat
Denali Has A Neurodegenerative Edge Despite Market Skepticism (NASDAQ:DNLI) - Seeking Alpha
Los Angeles Capital Management LLC Trims Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
State of New Jersey Common Pension Fund D Sells 25,613 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Capital Research Global Investors Expands Stake in Denali Therap - GuruFocus.com
NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears - GlobeNewswire
FMR LLC Expands Stake in Denali Therapeutics Inc - GuruFocus.com
BofA raises Denali Therapeutics target to $34 on BLA plans By Investing.com - Investing.com Canada
Denali Therapeutics executive sells shares worth $465,286 - Investing.com India
Denali Therapeutics executive sells shares worth $465,286 By Investing.com - Investing.com Canada
Finanzdaten der Denali Therapeutics Inc-Aktie (DNLI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Denali Therapeutics Inc-Aktie (DNLI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schuth Alexander O. | COFO and Secretary |
Nov 22 '24 |
Option Exercise |
0.68 |
20,516 |
13,951 |
198,582 |
| Schenkein David P | Director |
Nov 11 '24 |
Option Exercise |
18.00 |
47,165 |
848,970 |
68,661 |
| Schenkein David P | Director |
Nov 11 '24 |
Sale |
32.51 |
59,441 |
1,932,665 |
9,220 |
| Schuth Alexander O. | COFO and Secretary |
Nov 07 '24 |
Option Exercise |
5.28 |
15,558 |
82,146 |
193,624 |
| Schuth Alexander O. | COFO and Secretary |
Nov 07 '24 |
Sale |
29.91 |
15,558 |
465,286 |
178,066 |
| SATO VICKI L | Director |
Nov 07 '24 |
Sale |
30.00 |
1,020 |
30,600 |
111,056 |
1.03%
0.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):